Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Mar;71(3):1608-10.
doi: 10.1128/IAI.71.3.1608-1610.2003.

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

Samer Aboudola  1 , Karen L Kotloff, Lorraine Kyne, Michel Warny, Eoin C Kelly, Stavros Sougioultzis, Paul J Giannasca, Thomas P Monath, Ciarán P Kelly
Affiliations

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A

Samer Aboudola et al. Infect Immun. 2003 Mar.

Abstract

There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Serum anti-toxin A IgG concentrations following natural infection with C. difficile (left panel) or following vaccination with C. difficile toxoid (right panel). Results, expressed as ELISA units, are shown for control patients not infected with C. difficile (Control; n = 187), symptom-free carriers of C. difficile (CD carrier; n = 19), patients with recurrent C. difficile-associated diarrhea (Recurrent CDAD; n = 9), patients with a single episode of C. difficile-associated diarrhea (Single CDAD; n = 7), and healthy volunteers at various time points during vaccination with C. difficile toxoid (n = 30). The median values are depicted as bold horizontal lines, the boxes indicate the 25th and 75th percentiles, and the I bars indicate the 10th and 90th percentiles.
See this image and copyright information in PMC

References

    1. Aronsson, B., M. Granstrom, R. Mollby, and C. E. Nord. 1985. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13:97-101. - PubMed
    1. Bartlett, J. G. 2002. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346:334-339. - PubMed
    1. Johnson, S., D. N. Gerding, and E. N. Janoff. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J. Infect. Dis. 166:1287-1294. - PubMed
    1. Johnson, S., S. A. Kent, K. J. O'Leary, M. M. Merrigan, S. P. Sambol, L. R. Peterson, and D. N. Gerding. 2001. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med. 135:434-438. - PubMed
    1. Kelly, C. P. 1996. Immune response to Clostridium difficile infection. Eur. J. Gastroenterol. Hepatol. 8:1048-1053. - PubMed

Publication types

LinkOut - more resources